Silence Therapeutics (SLN) – Investment Analysts’ Recent Ratings Changes

Silence Therapeutics (NASDAQ: SLN) has recently received a number of price target changes and ratings updates:

• 3/7/2025 – Silence Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
• 3/5/2025 – Silence Therapeutics had its price target lowered by analysts at Morgan Stanley from $49.00 to $45.00. They now have an “overweight” rating on the stock.
• 3/4/2025 – Silence Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $6.00 to $4.00. They now have a “sell” rating on the stock.
• 3/4/2025 – Silence Therapeutics had its price target lowered by analysts at BMO Capital Markets from $67.00 to $25.00. They now have an “outperform” rating on the stock.
• 2/11/2025 – Silence Therapeutics is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “sell” rating and a $6.00 price target on the stock.
• 1/29/2025 – Silence Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.

Silence Therapeutics Stock Up 2.6 %

Shares of SLN stock traded up $0.09 during mid-day trading on Tuesday, reaching $3.58. The stock had a trading volume of 156,528 shares, compared to its average volume of 276,633. The firm has a market cap of $107.15 million, a PE ratio of -2.28 and a beta of 1.08. Silence Therapeutics plc has a one year low of $3.41 and a one year high of $24.38. The firm’s 50 day simple moving average is $4.78 and its 200 day simple moving average is $10.22.

Institutional Trading of Silence Therapeutics

Large investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC increased its holdings in Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock valued at $7,222,000 after purchasing an additional 849,676 shares in the last quarter. Eventide Asset Management LLC acquired a new position in Silence Therapeutics during the 3rd quarter valued at about $11,635,000. Redmile Group LLC raised its position in shares of Silence Therapeutics by 26.3% during the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock valued at $16,507,000 after acquiring an additional 500,000 shares during the last quarter. Bank of America Corp DE raised its position in shares of Silence Therapeutics by 48,165.6% during the 4th quarter. Bank of America Corp DE now owns 499,066 shares of the company’s stock valued at $3,434,000 after acquiring an additional 498,032 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after purchasing an additional 321,300 shares during the period. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.